CRISPR Therapeutics AG News - CRSP

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating...

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

jondoeuk 4 days ago

ASH abstract https://ash.confex.com/ash/2024/webprogram/Paper203563.html

👍️0

jondoeuk 4 days ago

Q3 business update and financial results https://www.globenewswire.com/news-release/2024/11/05/2974996/0/en/CRISPR-Therapeutics-Provides-Business-Update-and-Reports-Third-Quarter-2024-Financial-Results.html

👍️0

Monksdream 6 days ago

CRSP 10Q 11/5

👍️0

Monksdream 2 weeks ago

CRSP under $50

👍️0

jondoeuk 2 weeks ago

OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082

👍️ 1

TechandBio 2 months ago

CRSP will climb tremendously over the years.
SMMT went from $1.00-30.00+ this year cancer drug superior to Mercks Keytruda
ICCM company being over looked that kills cancers by freezing them 97% non recurrence rate for breast cancer after 5 years and superior data to lung cancer safe cryoblation is done in less than hour.
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html

👍️0

Monksdream 2 months ago

Buy range again thanks a bunch

👍️0

Monksdream 2 months ago

Buy range again thanks a bunch

👍️0

OldAIMGuy 2 months ago

Hi MD,
Here's a little longer view:

This might also be a cyclical low here. But, most of 2024 has shown severe distribution of shares until about the last month. That, at least, seems to be flattening out.
Best wishes,
OAG

👍️0

Monksdream 2 months ago

CRSP trend since February remains bearish

👍️0

jondoeuk 3 months ago

Q2 results https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200100452.html

👍️0

lambchops 3 months ago

Hey Monk, Hopefully you bought some shares on Friday@ Sold at 10% discount!

LC

CRISPR!!!

👍️0

Monksdream 3 months ago

CRSP under $75

👍️0

TechandBio 4 months ago

Crispr added some $120 Vertical debit spreads in 2026

$CRSP

👍️ 1

axelvento 5 months ago

I agree.....solid company$$$$$$$$

👍️0

Monksdream 5 months ago

It may take some time for CRSP returns to a $200 price tag
The same could be said for hundreds of other stocks that soared during Covid mania
Since then the stock has rallied from low points
With all that money the company has to do incredible things with its biotechnology the stock isn’t going to zero

👍️ 1

axelvento 6 months ago

Strong balance sheet with approximately $2.1 billion in cash, cash equivalents, and marketable securities as of March 31, 2024

https://finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000059.html

👍️0

jondoeuk 6 months ago

(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers.

👍️0

jondoeuk 6 months ago

Business Update and Q1 Financial Results https://uk.finance.yahoo.com/news/crispr-therapeutics-provides-business-reports-200000300.html

👍️0

jondoeuk 6 months ago

Highlights (plus new programs utilising in vivo gene editing) https://finance.yahoo.com/news/crispr-therapeutics-highlights-asgct-oral-110000066.html

👍️0

jondoeuk 7 months ago

https://www.globenewswire.com/news-release/2024/04/22/2867236/0/en/CRISPR-Therapeutics-to-Present-Oral-Presentation-at-the-American-Society-of-Gene-Cell-Therapy-ASGCT-2024-Annual-Meeting.html

EDIT is also pursuing myocilin-related glaucoma https://www.globenewswire.com/news-release/2024/04/22/2867244/0/en/Editas-Medicine-to-Present-Pre-clinical-Data-Demonstrating-Progression-of-in-vivo-Medicines-Pipeline-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

👍️0

OldAIMGuy 7 months ago

StockCharts 3 year history with 20% ZigZag reversals................

CRSP seems to be suffering from lack of 'sponsorship' in that the stock has not shown "accumulation" trend along with the price rally since last year's October Low. There's been volume, but not accumulation bias.

Best wishes,
OAG

👍️0

OldAIMGuy 7 months ago

Hi MD,
CRSP is now down around 1/3 from its February high. The price is where I usually start to accumulate more shares.

Best wishes,
OAG

👍️0

Monksdream 7 months ago

CRSP over $30

👍️0

jondoeuk 7 months ago

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-american-society-120000624.html

👍️0

Monksdream 9 months ago

CRSP new 52 week high

👍️0

Monksdream 9 months ago

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

👍️0

Monksdream 9 months ago

CRSP new 52 week high

👍️ 1

Monksdream 9 months ago

CRSP new 52 week high

👍️ 1

jondoeuk 9 months ago

They entered into an investment agreement for the sale of ~$280 million of its shares to a select group of institutional investors in a registered direct offering, at $71.5 apiece. The financing is being led by EcoR1 Capital and SR One with participation from existing investors and a healthcare specialist investor https://finance.yahoo.com/news/crispr-therapeutics-announces-280-million-133000932.html

👍️0

jondoeuk 9 months ago

EU approval https://finance.yahoo.com/news/european-commission-approves-first-crispr-065900771.html

👍️ 1

Monksdream 9 months ago

Didn’t tank like BLUE
Recovered

More analysis from Nanolyze

👍️0

Monksdream 9 months ago

So there has been some discussion since my last post
More in this podcast

🌈 1 🍆 1

jondoeuk 10 months ago

Around two months ahead of expectations https://www.globenewswire.com/news-release/2024/01/16/2810298/0/en/CRISPR-Therapeutics-Announces-U-S-Food-and-Drug-Administration-FDA-Approval-of-CASGEVY-exagamglogene-autotemcel-for-the-Treatment-of-Transfusion-Dependent-Beta-Thalassemia.html

👍️ 1

jondoeuk 10 months ago

Strategic Priorities and 2024 Outlook https://finance.yahoo.com/news/crispr-therapeutics-highlights-strategic-priorities-120000043.html

👍️0

jondoeuk 10 months ago

Webcast link https://jpmorgan.metameetings.net/events/healthcare24/sessions/49607-crispr-therapeutics-inc/webcast/general_signin?gpu_only=true&kiosk=true

👍️ 1

jondoeuk 10 months ago

Upcoming https://uk.finance.yahoo.com/news/crispr-therapeutics-present-42nd-annual-133000024.html

👍️0

JJ8 11 months ago

Good morning OAG,

Surprising and interesting. Share price sudden "jack-rabbit" moves in quick price reversals. The technical picture for today changed from positive breakout yesterday to "High Pole Warning" with sudden drop in price. Apparently the dominating group of participants seem to dictate this pace a bit unusual and different from other stocks. Yet it offers opportunity for profit once one has a good plan and strategy.

Good you have a plan and strategy for your preferred limits and ranges for your trading. Let's see how it goes. Have fun & GLTY

👍️ 1

OldAIMGuy 11 months ago

Good morning JJ8,

It needs to crest $85 or better to get me interested in reducing my share inventory. A drop to $57 will trigger an addition of 12% to share count.

I'd like to see it crest $72 and maintain that price right now.

Best wishes,
OAG

👍️0

JJ8 11 months ago

CRSP share price Double Top Breakout today on 19-Dec-2023. Happy Holidays & GLTA

👍️0

Monksdream 11 months ago

Oscar Wilde once observed that a cynic knows the price of everything and the value of nothing

👍️0

JJ8 11 months ago

Windbag1014,

Thanks for your views and informative response. GLTY & GLTA

👍️0

JJ8 11 months ago

OldAIMGuy,

Thanks for your clear and detailed response.

Your approach and strategy dealing with what Crispr T AG stock price movement over time shows, and the Crispr company activity makes good sense. More power and good luck to you.

John

👍️ 1

OldAIMGuy 11 months ago

Hi JJ8, Re: CRSP price action..........................

My guess is it's a "Sell on the News" action. This isn't the first time CRSP has shown high amplitude price change as this histogram shows:
https://schrts.co/NSfSbXYF

I think it will be important to watch the transition of this company from basically a 'research' business to one of product development and distribution. Somewhere along the way they'll have to show a profit to reward those who've invested in them. I'm fond of watching the Accumulation/Distribution activity to see what is happening with strong and weak hands holding the stock. In the mean time I plan on trimming and backfilling my position as the price moves around. I last added 12% to my position at $47.56 in August and had the opportunity to part with 10% of the holding at $69.57 a few weeks ago. The core position remains.

With each cycle of the price the portfolio builds out a bit.

Hope this helps,
OAG

👍️0

Windbag1014 11 months ago

Vertex set the price of Casgevy at $2.2 million compared to $3.1 million for Bluebird’s Lyfgenia. Bluebird’s gene therapy for thalassemia, approved last year, has a list price of $2.8 million.

The therapies are also not easy to receive. Patients must spend weeks, even months, in the hospital before and after the therapy is administered. And some of the preparatory steps can cause serious side effects, including severe infections, nausea, painful mouth sores, and infertility.

https://www.statnews.com/2023/12/08/fda-approves-casgevy-crispr-based-medicine-for-treatment-of-sickle-cell-disease/#:~:text=Vertex%20set%20the%20price%20of%20Casgevy%20at%20%242.2,year%2C%20has%20a%20list%20price%20of%20%242.8%20million.

Prohibitive treatment

👍️ 1

YankeMike 11 months ago

Probably just because the share price had run up so much before the approval, so it was kind of baked-in already and some took profits. Also, maybe because of high price tag of the treatment. Still a bright future and should trend upwards.

👍️0

JJ8 11 months ago

The dump of Crisp shares last Friday Dec 8th after the "good" news is confusing.

The institutional ownership is 63.48%. Why this response by share owners. I assume it probably was mainly by the institutions. But why at this time? Profit taking? Haven't done a check on insiders transactions yet.

More than 17 million shares traded in one session. The average daily volume of trading happens to be about 2-3 millions of shares daily. Why the exodus a this time of "good" news.

My profits were cut in half in one session. I don't intend to sell at such times.
Actually, I buy usually. That's what I did recently after the sudden drop in Walmart share price.

Any ideas and thoughts? What's going on behind the scene? TIA

GLTA

👍️0

Monksdream 11 months ago

Emmanuelle Charpentier, age 54, founder of Crispr Therapeutics AG

👍️ 1

TheFinalCD 11 months ago

Casgevy, developed by partners Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), and bluebird bio's (BLUE.) Lyfgenia were approved for people aged 12 years and older.
https://www.reuters.com/business/healthcare-pharmaceuticals/us-approves-two-gene-therapies-sickle-cell-disease-2023-12-08/

👍️0

JJ8 11 months ago

CRSP share price sharp reversal by Double Bottom Breakdown today on 8-Dec-2023. This type of rapid reversals based on company news developments. C'est La Vie in stock trading. GLTA

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CRISPR Therapeutics AG (CRSP)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CRSP News

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

CRSP Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

CRISPR Therapeutics AG (CRSP) News

CRISPR Therapeutics AG (CRSP)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CRSP News

Form 8-K - Current report

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

CRSP Discussion

Your Recent History

Company

Business

Popular

Get The App